Totally implantable central venous access devices in pediatric oncology--our experience in 46 patients

Area of Science:

• Pediatric Oncology
• Vascular Access Devices
• Cancer Therapy

Background:

• Venous access is crucial for administering chemotherapy and supportive care in pediatric cancer patients.
• Traditional venous access methods can be invasive and lead to complications.
• Implantable ports offer a solution for long-term venous access.

Purpose of the Study:

• To evaluate the safety and efficacy of implantable venous access devices in pediatric cancer patients.
• To compare the complication rates between "pediatric" and "adult" types of venous access devices.

Main Methods:

• A retrospective study of 50 venous access devices implanted in 46 children (45 with cancer, 1 with Langerhans cell histiocytosis) between 1986 and 1990.
• Devices included 25 "pediatric" and 25 "adult" ports.
• Data collected on implantation, duration of access, and complications.

Main Results:

• Total venous access duration was 15,024 patient-days.
• Overall complication rate was 24% (11 of 46 patients).
• Occlusion was the most frequent complication (11%). "Pediatric" systems accounted for 7 of 11 complications, including all 3 port occlusions.
• "Adult" access devices demonstrated safety and allowed for long-standing central venous access.

Conclusions:

• "Adult" venous access devices are safe and effective for long-term central venous access in pediatric cancer patients.
• Proper placement technique and nursing care are essential for minimizing complications.
• Implantable "adult" ports represent a significant improvement in pediatric cancer therapy.